Teva Turmoil: Shares Up, Board Trimmed, CEO To Retire

Teva Pharmaceutical Industries TEVA opened with a bang Wednesday when the Israeli genetics behemoth announced an early retirement for chief executive Philip Frost, whose term was set to expire next year.

The company has recently seen a share of turmoil. "The board of directors is like a nuthouse," Ori Hershkovitz, a managing partner at Sphera Funds Management told Bloomberg earlier this year.

Frost, in a letter to shareholders Wednesday, said he will step down "approximately by the end of the year." Frost holds 1.53 percent of Teva, making him the largest individual shareholder.

Frost, 77, also serves as Teva's chairman and had suggested earlier this year that he was considering the move. Frost took the CEO position in October 2013 after Teva's board fired Jeremy Levin.

Teva also said it will trim its board, naming Jean-Michel Halfon a director, while Chaim Hurvitz, Dan Suesskind and Dafna Schwartz will retire.

No CEO replacement has been announced.

Teva traded recently at $52.08 per share, up 1.21 percent.

Posted In: NewsManagement
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...